A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model

Authors Information
Article Notes and Dates
To Cite : Keshavarz K, Kebriaeezadeh A, Alavian S M, Akbari Sari A, Rezaei Hemami M, et al. A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model, Hepat Mon. 2016 ;16(9):e37435. doi: 10.5812/hepatmon.37435.
Copyright: Copyright © 2016, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Lok AS. Chronic hepatitis B. N Engl J Med. 2002; 346(22): 1682-3[DOI][PubMed]
  • 2. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007; 16(4): 403-6[PubMed]
  • 3. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997; 337(24): 1733-45[DOI][PubMed]
  • 4. Lai CL. Chronic hepatitis B in Hong Kong: immunization strategies for the control of hepatitis B virus infection. Hepatitis B Asian-Pacific region. 1997; 1: 79-87
  • 5. Keshavarz K, Kebriaeezadeh A, Alavian SM, Akbari Sari A, Abedin Dorkoosh F, Keshvari M, et al. Economic burden of hepatitis B virus-related diseases: evidence from iran. Hepat Mon. 2015; 15(4): 25854[DOI][PubMed]
  • 6. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus infection in Iran: A systematic review. Hepat Mon. 2008; 8(4): 281-94
  • 7. 2015;
  • 8. Alavian SM, Keyvani H, Rezai M, Ashayeri N, Sadeghi HM. Preliminary report of hepatitis B virus genotype prevalence in Iran. World J Gastroenterol. 2006; 12(32): 5211-3[PubMed]
  • 9. Haghshenas MR, Arabi M, Mousavi T. Hepatitis B genotypes in iran. Mater Sociomed. 2014; 26(2): 129-33[DOI][PubMed]
  • 10. Mohamadnejad M, Montazeri G, Fazlollahi A, Zamani F, Nasiri J, Nobakht H, et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol. 2006; 101(11): 2537-45[DOI][PubMed]
  • 11. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol. 2007; 21 Suppl C: 5-24[PubMed]
  • 12. He J, Bowen JM, Xie F, Goeree R. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. Value Health. 2012; 15(6): 894-906[DOI][PubMed]
  • 13. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010; 13(8): 922-33[DOI][PubMed]
  • 14. Yuan Y, Iloeje UH, Hay J, Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm. 2008; 14(1): 21-33[DOI][PubMed]
  • 15. Earnshaw J, Lewis G. NICE Guide to the Methods of Technology Appraisal: pharmaceutical industry perspective. Pharmacoeconomics. 2008; 26(9): 725-7[PubMed]
  • 16. Wiens A, Venson R, Correr CJ, Pontarolo R. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B. Braz J Infect Dis. 2011; 15(3): 225-30[PubMed]
  • 17. Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci. 2009; 14(4): 249-58[PubMed]
  • 18. Salem F, Hekmat S, Aghasadeghi MR, Javadi F, Gholami H, Mostafavi E. Prevalence and Risk Factors of Hepatitis B Virus Genotype D Amongst Inmates in Alborz Province, Iran: A Cross-Sectional Survey. Jundishapur J Microbiol. 2013; 6(6)[DOI]
  • 19. Abdoli G. Estimating the social discount rate for Iran [in Persian]. J Econ Res. 2009; 3: 135-56
  • 20. Robberstad B. Estimation of private and social time preferences for health in northern Tanzania. Soc Sci Med. 2005; 61(7): 1597-607[DOI][PubMed]
  • 21. Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian MA, Henry D, et al. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. Daru. 2013; 21(1): 50[DOI][PubMed]
  • 22. Mohammadnezhad M, Malekzadeh Z. Guidelines On The Management Of Chronic Hepatitis B [in Persian]. Govaresh J. 19(2): 128-40
  • 23. Bobes J, Canas F, Rejas J, Mackell J. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(8): 1287-97[DOI][PubMed]
  • 24. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007; 13(3): 245-61[DOI][PubMed]
  • 25. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health. 2002; 5(1): 44-54[DOI][PubMed]
  • 26. Nikfar S. A new model for decision analysis in economic evaluations of switchable health interventions. J Med Hypotheses Ideas. 2012; 6(1): 12-5[DOI]
  • 27. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007; 46(1): 254-65[DOI][PubMed]
  • 28. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009; 137(5): 1593-608[DOI][PubMed]
  • 29. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology. 2008; 134(2): 405-15[DOI][PubMed]
  • 30. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1): 167-85[DOI][PubMed]
  • 31. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012; 12(4): 341-53[DOI][PubMed]
  • 32. Berg T, Möller B, Gerken G, Jung MC, Spengler U, Hartmann H, et al. Tenofovir disoproxil fumarate (TDF) versus Emtricitabine plus TDF for treatment of chronic Hepatitis B (CHB) in subjects with persistent viral replication receiving Adefovir dipivoxil (ADV). Zeitschrift Gastroenterol. 2008; 46(9)[DOI]
  • 33. Sung JJY, Lai JY, Zeuzem S, Chow WC, Heathcote E, Perrillo R, et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysis. J Hepatol. 2003; 38: 25-6[DOI]
  • 34. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005; 129(2): 528-36[DOI][PubMed]
  • 35. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010; 139(4): 1218-29[DOI][PubMed]
  • 36. Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health. 2010; 13(8): 934-45[DOI][PubMed]
  • 37. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359(23): 2442-55[DOI][PubMed]
  • 38. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3): 678-86[DOI][PubMed]
  • 39. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354(10): 1001-10[DOI][PubMed]
  • 40. Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol. 2010; 53(1): 118-25[DOI][PubMed]
  • 41. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011; 12(6): 568-74[DOI][PubMed]
  • 42. Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, et al. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ. 2012; 13(5): 663-76[DOI][PubMed]
  • 43. Yurdaydin C, Bozkaya H, Cetinkaya H, Sahin T, Karaoguz D, Toruner M, et al. Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. J Viral Hepat. 2005; 12(3): 262-8[DOI][PubMed]
  • 44. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007; 147(11): 745-54[PubMed]
  • 45. Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008; 11(3): 527-38[DOI][PubMed]
  • 46. Chen CJ, Yang HI, Iloeje UH, Reveal-Hbv Study Group . Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009; 49(5 Suppl): 72-84[DOI][PubMed]
  • 47. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med. 2005; 142(10): 821-31[PubMed]
  • 48. Lynch SV, Balderson GA. ANZLT Registry Report 2007 2007;
  • 49. Sali S, Alavian SM, Foster GR, Keyvani H, Mehrnoosh L, Mohammadi N. Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up. Hepat Mon. 2013; 13(7): 8743[DOI][PubMed]
  • 50. Life tables by country Iran (Islamic Republic of).
  • 51. Duberg AS, Torner A, Davidsdottir L, Aleman S, Blaxhult A, Svensson A, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat. 2008; 15(7): 538-50[DOI][PubMed]
  • 52. Sun X, Faunce T. Decision-analytical modelling in health-care economic evaluations. Eur J Health Econ. 2008; 9(4): 313-23[DOI][PubMed]
  • 53. Goudarzi R. Estimating quality weights for EQ-5D health states with the time trade-off (TTO) method in Iran [Dissertation]. 2014;
  • 54. The Rate Currency.
  • 55. PPP conversion factor, private consumption (LCU per international $).
  • 56. Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol. 2009; 51(4): 640-6[DOI][PubMed]
  • 57. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics. 2009; 27(11): 903-17[DOI][PubMed]
  • 58. Tantai N, Chaikledkaew U, Tanwandee T, Werayingyong P, Teerawattananon Y. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. BMC Health Serv Res. 2014; 14: 170[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check